| Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
|
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
